WCM
PTGX icon

Weld Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Weld Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-31,488
Closed -$222K – 650
2019
Q4 		$222K Buy
+31,488
New +$313K 0.04% 519

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Weld Capital Management's PTGX Position: Q1 2020 in Review

Weld Capital Management sold out of Protagonist Therapeutics (PTGX) in Q1 2020, closing a stake of 31,488 shares — an estimated $222K sold.

Weld Capital Management first reported a position in PTGX in Q4 2019 and held it in 1 quarter. The position peaked at $222K in Q4 2019. 77 funds tracked by Wall St. Rank hold PTGX as of Q1 2020.

  • Weld Capital Management reported no remaining Protagonist Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Weld Capital Management sold 31,488 Protagonist Therapeutics shares in Q1 2020, an estimated $222K.
  • Weld Capital Management first reported a position in Protagonist Therapeutics in Q4 2019 and held it in 1 quarter.
  • Weld Capital Management's Protagonist Therapeutics position peaked at $222K in Q4 2019.
  • 77 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2020.

Based on Weld Capital Management's 13F filing for Q1 2020, filed 15 May 2020.